查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930148

全球药物基因组学市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Pharmacogenomics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 130 Pages | 商品交期: 请询问到货日

价格

药物基因体学市场成长因素

全球药物基因组学市场正经历强劲成长，这主要得益于个人化医疗的快速发展和基因组学技术的进步。 2025年，该市场规模为34.6亿美元，预计2026年将成长至37.9亿美元，到2034年将达到80.9亿美元，在预测期（2026-2034年）内复合年增长率（CAGR）为9.95%。北美地区在2025年占市场主导地位，市场占有率达39.47%，这得益于其先进的医疗基础设施、精准医疗的早期应用以及有利的监管支持。

药物基因组学研究患者的基因组成与其对药物的反应之间的关係，使医疗保健提供者能够优化药物选择和剂量，同时最大限度地减少副作用。对标靶治疗日益增长的需求、慢性疾病负担的加重以及基因组研究的大规模投资，都在显着推动市场成长。

市场动态

市场驱动因素

药物基因体学市场的一个关键驱动因素是对个人化医疗的重视。全球医疗保健系统正逐步从通用治疗方法转向基于基因的疗法，以提高疗效和安全性。下一代定序 (NGS) 和生物资讯学的进步显着降低了定序成本和周转时间，使药物基因组学检测更加普及。

此外，人口老化加剧以及癌症和心血管疾病等慢性疾病盛行率的上升，正在加速对基于精准医疗的治疗决策的需求。 大型企业的策略性举措也正在进一步推动市场扩张。例如，2025年6月，生物梅里埃宣布收购Day Zero Diagnostics，以加强其基于基因组定序的诊断产品组合。

市场限制因子

儘管技术不断进步，但基因检测和结果解读缺乏标准化仍然是市场面临的挑战。不同实验室的研究方法和报告框架不一致，限制了临床医生利用药物基因组学数据进行治疗决策的信心。此外，不同地区缺乏统一的报销政策和监管指南也阻碍了其广泛应用。

市场机会

人工智慧 (AI) 与药物基因组学的融合带来了巨大的成长机会。 AI驱动的平台可以分析大型基因组资料集，以识别基因-药物交互作用、预测治疗结果并优化给药方案。对基于AI的精准医疗解决方案的投入增加有望释放新的发展机会。

例如，2024 年 12 月，PGxAI, Inc. 从 InterSystems 获得了 150 万美元的融资，用于增强其专有的 AI 驱动的药物基因组学演算法。

市场挑战

限制市场扩张的一个关键挑战是药物基因组学资料与电子健康记录 (EHR) 系统整合的难度。有限的互通性阻碍了在临床诊疗点轻鬆利用基因资讯。儘管目前正在努力改善数据整合，但临床决策支援工具普及程度的不均衡仍然是其广泛应用的一大障碍。

药物基因体学市场趋势

影响市场的一个关键趋势是药物基因组学生物标记在临床试验和药物开发中的应用日益广泛。 FDA 和 EMA 等监管机构鼓励将基因终点纳入药物标籤和伴随诊断。这一趋势正在推动药物疗效的提高、试验失败率的降低以及监管审批速度的加速。

例如，2024 年 8 月，Illumina 的综合检测产品 "TruSight Oncology" 获得 FDA 批准，能够分析 500 多个基因。这表明基因组学在以肿瘤学为重点的药物基因组学领域的重要性日益凸显。

细分市场分析

依服务划分，由于对基因数据解读和临床报告的需求不断增长，服务业在 2024 年占市场主导地位。

依技术划分，能够同时分析多种基因突变的下一代定序 (NGS) 占了相当大的市场占有率。

依应用划分，个人化医疗在个人化治疗趋势的推动下引领市场。

依疾病划分，由于癌症具有很强的遗传基础以及对标靶癌症疗法的需求不断增长，肿瘤学在 2024 年占了最大的市场占有率。

依最终用户划分，学术研究机构在基因组学研究和政府资助的研究支持下，占市场主导地位。

区域展望

北美预计将引领市场，2025年市场规模将达到13.6亿美元，2026年将达到14.9亿美元，主要得益于高额的医疗保健支出、强大的研究基础设施和监管支持。

欧洲预计将占较大占有率，这主要归功于合作基因组研究计划和有利的医疗保健政策。

亚太地区预计将在预测期内实现最高的复合年增长率，这主要得益于中国、日本和印度等国家不断增加的医疗保健投资和国家基因组计划。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要公司新产品发布
  • 产业重大发展（併购、合作等）
  • 技术进步

第五章：全球药物基因体学市场分析：洞察与预测（2021-2034）

  • 市场分析,洞察与预测：依类型
    • 产品
      • 耗材
      • 设备
    • 服务
  • 市场分析、洞察与预测：依技术
    • 次世代定序
    • 聚合酶炼式反应 (PCR)
    • 微阵列
    • 原位杂交
    • 其他
  • 市场分析、洞察与预测：依应用
    • 个人化医疗
    • 药物研发
    • 其他
  • 市场分析、洞察与预测：依疾病
    • 肿瘤学
    • 神经系统疾病
    • 心臟疾病
    • 其他
  • 市场分析、洞察与预测：依最终用户用户
    • 学术和研究机构
    • 製药和生技公司
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美药物基因体学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第七章 亚太药物基因体学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第八章 拉丁美洲药物基因体学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第九章 中东与非洲药物基因体学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）国家
    • 南亚国家非洲
    • 其他中东和非洲地区

第十章：竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Hoffmann-La Roche Ltd.
    • Illumina
    • Thermo Fisher Scientific
    • Qiagen
    • Agilent Technologies
    • Myriad Genetics
    • Admera Health, LLC
    • Bio-Rad Laboratories Inc.
    • Eurofins Scientific
    • Pathway Genomics
    • Other Prominent Players
Product Code: FBI106937

Growth Factors of pharmacogenomics Market

The global pharmacogenomics market is experiencing robust growth, driven by the rapid shift toward personalized medicine and advancements in genomic technologies. The market was valued at USD 3.46 billion in 2025 and is projected to grow to USD 3.79 billion in 2026, reaching USD 8.09 billion by 2034, registering a strong CAGR of 9.95% during the forecast period (2026-2034). North America dominated the market, accounting for a 39.47% share in 2025, supported by advanced healthcare infrastructure, early adoption of precision medicine, and favorable regulatory support.

Pharmacogenomics studies the relationship between a patient's genetic makeup and their response to medications, enabling healthcare providers to optimize drug selection and dosage while minimizing adverse effects. The increasing demand for targeted therapies, rising burden of chronic diseases, and extensive investments in genomic research are significantly fueling market growth.

Market Dynamics

Market Drivers

A major driver of the pharmacogenomics market is the strong emphasis on personalized medicine. Healthcare systems worldwide are increasingly moving away from generalized treatment approaches toward genetically guided therapies that improve efficacy and safety. Advancements in next-generation sequencing (NGS) and bioinformatics have significantly reduced sequencing costs and turnaround times, making pharmacogenomic testing more accessible.

Additionally, the growing geriatric population and increasing prevalence of chronic diseases such as cancer and cardiovascular disorders are accelerating the need for precision-based treatment decisions. Strategic initiatives by key players are further supporting market expansion. For instance, in June 2025, bioMerieux announced the acquisition of Day Zero Diagnostics to strengthen its genome sequencing-based diagnostics portfolio.

Market Restraints

Despite technological progress, the market faces challenges due to the lack of standardization in genetic testing and result interpretation. Variability in testing methodologies and reporting frameworks across laboratories creates inconsistencies, limiting clinicians' confidence in using pharmacogenomic data for treatment decisions. Additionally, the absence of uniform reimbursement policies and regulatory guidelines across regions continues to restrain widespread adoption.

Market Opportunities

The integration of artificial intelligence (AI) with pharmacogenomics presents a significant growth opportunity. AI-driven platforms can analyze large genomic datasets to identify gene-drug interactions, predict treatment outcomes, and optimize dosage regimens. Increasing investments in AI-based precision medicine solutions are expected to unlock new development opportunities.

For example, in December 2024, PGxAI raised USD 1.5 million in funding to enhance its proprietary AI-driven pharmacogenomics algorithms in collaboration with InterSystems.

Market Challenges

A major challenge limiting market scalability is the difficulty in integrating pharmacogenomic data with electronic health record (EHR) systems. Limited interoperability prevents genetic insights from being readily accessible at the point of care. Although initiatives are underway to improve data integration, inconsistent adoption of clinical decision support tools continues to hinder full-scale implementation.

Pharmacogenomics Market Trends

A key trend shaping the market is the increasing incorporation of pharmacogenomic biomarkers in clinical trials and drug development. Regulatory bodies such as the FDA and EMA are encouraging the integration of genetic endpoints in drug labeling and companion diagnostics. This trend is enhancing drug efficacy, reducing trial failures, and accelerating regulatory approvals.

For instance, in August 2024, Illumina received FDA approval for its TruSight Oncology comprehensive test, capable of analyzing over 500 genes, highlighting the growing importance of genomics in oncology-focused pharmacogenomics.

Segmentation Analysis

By type, the services segment dominated the market in 2024 due to rising demand for genetic data interpretation and clinical reporting.

By technique, next-generation sequencing (NGS) held a significant market share owing to its ability to analyze multiple genetic variants simultaneously.

By application, personalized medicine dominated the market, driven by the shift toward tailored therapies.

By disease, oncology accounted for the largest share in 2024 due to the strong genetic basis of cancer and growing demand for targeted cancer therapies.

By end-user, academic and research institutes led the market, supported by extensive genomic research and government-funded studies.

Regional Outlook

North America led the market with a valuation of USD 1.36 billion in 2025 and USD 1.49 billion in 2026, driven by high healthcare expenditure, strong research infrastructure, and regulatory support.

Europe held a significant share due to collaborative genomic initiatives and favorable healthcare policies.

Asia Pacific is expected to register the highest CAGR during the forecast period, supported by rising healthcare investments and national genomics programs in countries such as China, Japan, and India.

Competitive Landscape

The market is moderately consolidated, with key players such as Illumina, Thermo Fisher Scientific, Qiagen, and F. Hoffmann-La Roche Ltd. holding substantial market share. These companies are focusing on strategic collaborations, technology sharing, and portfolio expansion to strengthen their market presence.

Conclusion

The global pharmacogenomics market is set for significant expansion, driven by the accelerating adoption of personalized medicine, advancements in sequencing technologies, and growing integration of genomics into clinical decision-making. While challenges related to standardization, data integration, and reimbursement persist, emerging opportunities in AI-enabled pharmacogenomics and expanding applications in oncology and chronic disease management are expected to sustain market growth. With strong investments in research, supportive regulatory initiatives, and increasing clinical adoption, the pharmacogenomics market is poised to witness robust growth through 2034, reinforcing its critical role in the future of precision healthcare.

Segmentation By Type

  • Products
    • Consumables
    • Equipment
  • Services

By Technique

  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Microarrays
  • In-situ Hybridization
  • Others

By Application

  • Personalized Medicine
  • Drug Discovery
  • Others

By Disease

  • Oncology
  • Neurology
  • Cardiology
  • Others

By End-user

  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Others

By Region

  • North America (By Type, Technique, Application, Disease, End-user, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Technique, Application, Disease, End-user, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Type, Technique, Application, Disease, End-user, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Type, Technique, Application, Disease, End-user, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Technique, Application, Disease, End-user, and Country/Sub-region)
    • GCC
    • South Africa
    • Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. New Product Launches, By Key Players
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
  • 4.3. Technological Advancements

5. Global Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Products
      • 5.1.1.1. Consumables
      • 5.1.1.2. Equipment
    • 5.1.2. Services
  • 5.2. Market Analysis, Insights and Forecast - By Technique
    • 5.2.1. Next Generation Sequencing
    • 5.2.2. Polymerase Chain Reaction
    • 5.2.3. Microarrays
    • 5.2.4. In-situ Hybridization
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Personalized Medicine
    • 5.3.2. Drug Discovery
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Disease
    • 5.4.1. Oncology
    • 5.4.2. Neurology
    • 5.4.3. Cardiology
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By End-user
    • 5.5.1. Academic and Research Institutes
    • 5.5.2. Pharmaceutical and Biotechnology Companies
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Products
      • 6.1.1.1. Consumables
      • 6.1.1.2. Equipment
    • 6.1.2. Services
  • 6.2. Market Analysis, Insights and Forecast - By Technique
    • 6.2.1. Next Generation Sequencing
    • 6.2.2. Polymerase Chain Reaction
    • 6.2.3. Microarrays
    • 6.2.4. In-situ Hybridization
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Personalized Medicine
    • 6.3.2. Drug Discovery
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Disease
    • 6.4.1. Oncology
    • 6.4.2. Neurology
    • 6.4.3. Cardiology
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By End-user
    • 6.5.1. Academic and Research Institutes
    • 6.5.2. Pharmaceutical and Biotechnology Companies
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 6.6.1. U.K.
    • 6.6.2. Germany
    • 6.6.3. France
    • 6.6.4. Spain
    • 6.6.5. Italy
    • 6.6.6. Scandinavia
    • 6.6.7. Rest of Europe

7. Asia Pacific Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Products
      • 7.1.1.1. Consumables
      • 7.1.1.2. Equipment
    • 7.1.2. Services
  • 7.2. Market Analysis, Insights and Forecast - By Technique
    • 7.2.1. Next Generation Sequencing
    • 7.2.2. Polymerase Chain Reaction
    • 7.2.3. Microarrays
    • 7.2.4. In-situ Hybridization
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Personalized Medicine
    • 7.3.2. Drug Discovery
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Disease
    • 7.4.1. Oncology
    • 7.4.2. Neurology
    • 7.4.3. Cardiology
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By End-user
    • 7.5.1. Academic and Research Institutes
    • 7.5.2. Pharmaceutical and Biotechnology Companies
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. Australia
    • 7.6.5. Southeast Asia
    • 7.6.6. Rest of Asia Pacific

8. Latin America Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Products
      • 8.1.1.1. Consumables
      • 8.1.1.2. Equipment
    • 8.1.2. Services
  • 8.2. Market Analysis, Insights and Forecast - By Technique
    • 8.2.1. Next Generation Sequencing
    • 8.2.2. Polymerase Chain Reaction
    • 8.2.3. Microarrays
    • 8.2.4. In-situ Hybridization
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Personalized Medicine
    • 8.3.2. Drug Discovery
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Disease
    • 8.4.1. Oncology
    • 8.4.2. Neurology
    • 8.4.3. Cardiology
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By End-user
    • 8.5.1. Academic and Research Institutes
    • 8.5.2. Pharmaceutical and Biotechnology Companies
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. Brazil
    • 8.6.2. Mexico
    • 8.6.3. Rest of Latin America

9. Middle East & Africa Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Products
      • 9.1.1.1. Consumables
      • 9.1.1.2. Equipment
    • 9.1.2. Services
  • 9.2. Market Analysis, Insights and Forecast - By Technique
    • 9.2.1. Next Generation Sequencing
    • 9.2.2. Polymerase Chain Reaction
    • 9.2.3. Microarrays
    • 9.2.4. In-situ Hybridization
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Personalized Medicine
    • 9.3.2. Drug Discovery
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Disease
    • 9.4.1. Oncology
    • 9.4.2. Neurology
    • 9.4.3. Cardiology
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By End-user
    • 9.5.1. Academic and Research Institutes
    • 9.5.2. Pharmaceutical and Biotechnology Companies
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. GCC
    • 9.6.2. South Africa
    • 9.6.3. Rest of Middle East & Africa

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Hoffmann-La Roche Ltd.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Illumina
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Thermo Fisher Scientific
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Qiagen
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Agilent Technologies
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Myriad Genetics
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Admera Health, LLC
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Bio-Rad Laboratories Inc.
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Eurofins Scientific
      • 10.2.9.1. Overview
      • 10.2.9.2. Products
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)
    • 10.2.10. Pathway Genomics
      • 10.2.10.1. Overview
      • 10.2.10.2. Products
      • 10.2.10.3. SWOT Analysis
      • 10.2.10.4. Recent Developments
      • 10.2.10.5. Strategies
      • 10.2.10.6. Financials (Based on Availability)
    • 10.2.11. Other Prominent Players
      • 10.2.11.1. Overview
      • 10.2.11.2. Products
      • 10.2.11.3. SWOT Analysis
      • 10.2.11.4. Recent Developments
      • 10.2.11.5. Strategies
      • 10.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 3: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 4: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 5: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 6: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 7: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 9: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 10: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 11: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 12: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 13: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 14: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 15: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 16: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 17: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 18: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 20: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 21: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 22: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 23: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 24: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 25: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 26: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 27: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 28: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 29: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 30: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 31: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 32: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 33: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 34: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 35: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 36: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 37: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 38: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 39: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 40: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 41: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 42: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Pharmacogenomics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Pharmacogenomics Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Pharmacogenomics Market Value Share (%), by Type, 2025
  • Figure 4: Global Pharmacogenomics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 5: Global Pharmacogenomics Market Value Share (%), by Technique, 2025
  • Figure 6: Global Pharmacogenomics Market Value Share (%), by Application, 2025 & 2034
  • Figure 7: Global Pharmacogenomics Market Value Share (%), by Application, 2025
  • Figure 8: Global Pharmacogenomics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 9: Global Pharmacogenomics Market Value Share (%), by Disease, 2025
  • Figure 10: Global Pharmacogenomics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 11: Global Pharmacogenomics Market Value Share (%), by End-user, 2025
  • Figure 12: Global Pharmacogenomics Market Value Share (%), by Region, 2025 & 2034
  • Figure 13: Global Pharmacogenomics Market Value Share (%), by Region, 2025
  • Figure 14: North America Pharmacogenomics Market Value Share (%), by Type, 2025 & 2034
  • Figure 15: North America Pharmacogenomics Market Value Share (%), by Type, 2025
  • Figure 16: North America Pharmacogenomics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 17: North America Pharmacogenomics Market Value Share (%), by Technique, 2025
  • Figure 18: North America Pharmacogenomics Market Value Share (%), by Application, 2025 & 2034
  • Figure 19: North America Pharmacogenomics Market Value Share (%), by Application, 2025
  • Figure 20: North America Pharmacogenomics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 21: North America Pharmacogenomics Market Value Share (%), by Disease, 2025
  • Figure 22: North America Pharmacogenomics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 23: North America Pharmacogenomics Market Value Share (%), by End-user, 2025
  • Figure 24: North America Pharmacogenomics Market Value Share (%), by Country, 2025 & 2034
  • Figure 25: North America Pharmacogenomics Market Value Share (%), by Country, 2025
  • Figure 26: Europe Pharmacogenomics Market Value Share (%), by Type, 2025 & 2034
  • Figure 27: Europe Pharmacogenomics Market Value Share (%), by Type, 2025
  • Figure 28: Europe Pharmacogenomics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 29: Europe Pharmacogenomics Market Value Share (%), by Technique, 2025
  • Figure 30: Europe Pharmacogenomics Market Value Share (%), by Application, 2025 & 2034
  • Figure 31: Europe Pharmacogenomics Market Value Share (%), by Application, 2025
  • Figure 32: Europe Pharmacogenomics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 33: Europe Pharmacogenomics Market Value Share (%), by Disease, 2025
  • Figure 34: Europe Pharmacogenomics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 35: Europe Pharmacogenomics Market Value Share (%), by End-user, 2025
  • Figure 36: Europe Pharmacogenomics Market Value Share (%), by Country, 2025 & 2034
  • Figure 37: Europe Pharmacogenomics Market Value Share (%), by Country, 2025
  • Figure 38: Asia Pacific Pharmacogenomics Market Value Share (%), by Type, 2025 & 2034
  • Figure 39: Asia Pacific Pharmacogenomics Market Value Share (%), by Type, 2025
  • Figure 40: Asia Pacific Pharmacogenomics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 41: Asia Pacific Pharmacogenomics Market Value Share (%), by Technique, 2025
  • Figure 42: Asia Pacific Pharmacogenomics Market Value Share (%), by Application, 2025 & 2034
  • Figure 43: Asia Pacific Pharmacogenomics Market Value Share (%), by Application, 2025
  • Figure 44: Asia Pacific Pharmacogenomics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 45: Asia Pacific Pharmacogenomics Market Value Share (%), by Disease, 2025
  • Figure 46: Asia Pacific Pharmacogenomics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 47: Asia Pacific Pharmacogenomics Market Value Share (%), by End-user, 2025
  • Figure 48: Asia Pacific Pharmacogenomics Market Value Share (%), by Country, 2025 & 2034
  • Figure 49: Asia Pacific Pharmacogenomics Market Value Share (%), by Country, 2025
  • Figure 50: Latin America Pharmacogenomics Market Value Share (%), by Type, 2025 & 2034
  • Figure 51: Latin America Pharmacogenomics Market Value Share (%), by Type, 2025
  • Figure 52: Latin America Pharmacogenomics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 53: Latin America Pharmacogenomics Market Value Share (%), by Technique, 2025
  • Figure 54: Latin America Pharmacogenomics Market Value Share (%), by Application, 2025 & 2034
  • Figure 55: Latin America Pharmacogenomics Market Value Share (%), by Application, 2025
  • Figure 56: Latin America Pharmacogenomics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 57: Latin America Pharmacogenomics Market Value Share (%), by Disease, 2025
  • Figure 58: Latin America Pharmacogenomics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 59: Latin America Pharmacogenomics Market Value Share (%), by End-user, 2025
  • Figure 60: Latin America Pharmacogenomics Market Value Share (%), by Country, 2025 & 2034
  • Figure 61: Latin America Pharmacogenomics Market Value Share (%), by Country, 2025
  • Figure 62: Middle East and Africa Pharmacogenomics Market Value Share (%), by Type, 2025 & 2034
  • Figure 63: Middle East and Africa Pharmacogenomics Market Value Share (%), by Type, 2025
  • Figure 64: Middle East and Africa Pharmacogenomics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 65: Middle East and Africa Pharmacogenomics Market Value Share (%), by Technique, 2025
  • Figure 66: Middle East and Africa Pharmacogenomics Market Value Share (%), by Application, 2025 & 2034
  • Figure 67: Middle East and Africa Pharmacogenomics Market Value Share (%), by Application, 2025
  • Figure 68: Middle East and Africa Pharmacogenomics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 69: Middle East and Africa Pharmacogenomics Market Value Share (%), by Disease, 2025
  • Figure 70: Middle East and Africa Pharmacogenomics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 71: Middle East and Africa Pharmacogenomics Market Value Share (%), by End-user, 2025
  • Figure 72: Middle East and Africa Pharmacogenomics Market Value Share (%), by Country, 2025 & 2034
  • Figure 73: Middle East and Africa Pharmacogenomics Market Value Share (%), by Country, 2025
  • Figure 74: Global Pharmacogenomics Market Share (%), By Company, 2025